当前位置: X-MOL 学术Curr. Opin. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
HBV as a target for CAR or TCR-T cell therapy.
Current Opinion in Immunology ( IF 6.6 ) Pub Date : 2020-04-30 , DOI: 10.1016/j.coi.2020.04.003
Antonio Bertoletti 1 , Anthony Tanoto Tan 2
Affiliation  

Engineering HBV-specific T cells utilizing a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) provides a well characterized, sizeable and functionally intact population of HBV-specific T cells with identical in vitro functionality to the T cells isolated in patients who resolved acute HBV infection. In this review we present evidences of the virological and immunological features of chronic HBV infection, alone or in combination with Hepatitis Delta that might make it amenable for CAR/TCR-T cells therapy.

中文翻译:

HBV 作为 CAR 或 TCR-T 细胞治疗的靶点。

利用嵌合抗原受体 (CAR) 或经典 T 细胞受体 (TCR) 对 HBV 特异性 T 细胞进行工程改造,提供了一个特征明确、规模大且功能完整的 HBV 特异性 T 细胞群,其体外功能与分离的 T 细胞相同。治愈急性HBV感染的患者。在这篇综述中,我们提出了慢性 HBV 感染的病毒学和免疫学特征的证据,单独或与肝炎三角洲联合使用,可能使其适用于 CAR/TCR-T 细胞治疗。
更新日期:2020-04-30
down
wechat
bug